NCT00669409 - A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2008

Primary Completion Date

December 25, 2009

Study Completion Date

December 25, 2009

Conditions

Osteoarthritis, Knee

Interventions

DRUG

PF-04383119 (tanezumab)

single dose of 10 mcg/kg IV

DRUG

PF-04383119 (tanezumab)

single dose of 100 mcg/kg IV

DRUG

PF-04383119 (tanezumab)

single dose of 200 mcg/kg IV

DRUG

PF-04383119 (tanezumab)

single dose of 25 mcg/kg IV

DRUG

PF-04383119 (tanezumab)

single dose of 50 mcg/kg IV

DRUG

PF-04383119 (tanezumab)

single dose of Placebo IV

Trial Locations (12)

370-0829

National Hospital Organization Takasaki General Medical Center, Takasaki

252-0802

Fujisawa shounandai Hospital, Fujisawa-shi

210-0852

Nippon Kokan Clinic, Kawasaki

224-0024

Medical Corporation Yamamoto Kinenkai Yamamoto Kinen Hospital, Yokohama

874-0937

Nakamura Hospital, Beppu-shi

183-8524

Tokyo Metropolitan Fuchu Hospital, Fuchū

106-8581

FuruKawabashi Hospital, Minato-ku

108-8639

Research Hospital, the Institute of Medical Science, the University of Tokyo, Minato-ku

140-0001

Kitashinagawa Third Hospital, Shinagawa-ku

141-0001

Oosaki Hospital Tokyo Heart Center, Shinagawa-ku

141-8625

Kanto Medical Center Ntt Ec, Shinagawa-ku

162-8655

International Medical Center of Japan Toyama Hospital, Shinjuku-ku